Trans fatty acids
This article was originally published in The Tan Sheet
Executive Summary
Providing a separate line item on food nutrition facts labeling for trans fat information is preferred over combining trans fat levels with saturated fat, FTC's Bureaus of Economics and Consumer Protection say in April 17 comments on FDA's proposed rule. FTC staff also recommend FDA consider a health claim regarding the potential link between trans fatty acids and heart disease to help consumers make more informed choices. Published Nov. 7, the proposed rule would affect products containing .5 g or more trans fat per serving, and would prohibit products with over 4 g saturated and trans fat combined from making positive health claims (1"The Tan Sheet" Nov. 15, 1999, In Brief)
You may also be interested in...
Trans fatty acids
Food marketers would be required to disclose the trans fatty acids content of products in the "Nutrition Facts" panel under an FDA proposed rule expected to be published in the Nov. 17 Federal Register. The levels of trans fat also would be considered when attempting to meet the requirements for claims regarding "low saturated fat" and "reduced saturated fat," as well as "lean," "extra lean" and cholesterol claims. Products containing more than 4 g saturated and trans fat combined per serving additionally would be prohibited from making health claims, such as the approved claim for calcium and osteoporosis. The public comment period on the proposal will run for 90 days
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands